Last updated: November 3, 2026
Romazicon is the original U.S. brand for flumazenil, a benzodiazepine antagonist used to reverse benzodiazepine-induced sedation and, in selected cases, manage benzodiazepine overdose. The product is a mature injectable medicine with limited brand value, no meaningful remaining exclusivity, and competition from generic flumazenil injection. Its commercial profile is driven by hospital demand, procedural sedation volumes, emergency-department use, supplier reliability, and reimbursement rather than by branded pharmaceutical marketing.
No reliable public source reports standalone Romazicon revenue. Roche does not separately disclose Romazicon sales in its current financial reporting, and generic manufacturers generally report flumazenil revenue within broader hospital-injectable portfolios. The financial trajectory is therefore best assessed through product maturity, generic competition, procurement dynamics, and supply risk.
What is Romazicon and how is flumazenil used?
Romazicon contains flumazenil, a competitive antagonist at the benzodiazepine receptor site on the GABA-A receptor complex. It reverses the sedative, hypnotic, and anesthetic effects of benzodiazepines.
The FDA-approved clinical uses include:
- Reversal of sedation after diagnostic or therapeutic procedures
- Reversal of benzodiazepine effects in general anesthesia
- Management of suspected or known benzodiazepine overdose in appropriate clinical settings
Romazicon is administered intravenously. The product is used primarily by hospitals, ambulatory surgery centers, emergency departments, anesthesiology departments, and intensive-care units. It is not a chronic-use medicine and does not generate recurring retail prescriptions.
The product has clinical limitations. Flumazenil can precipitate withdrawal, seizures, agitation, or acute benzodiazepine withdrawal in dependent patients. It may also unmask toxicity from co-ingested drugs. These restrictions limit routine use in undifferentiated overdose cases and support continued reliance on airway management, monitoring, and supportive care. [1]
What is the FDA and Orange Book status of Romazicon?
Romazicon is a mature FDA-approved small-molecule injectable product. Its regulatory exclusivity expired long ago, and generic flumazenil products are available in the United States.
| Regulatory attribute |
Romazicon status |
| Active ingredient |
Flumazenil |
| Dosage form |
Intravenous injection |
| Therapeutic class |
Benzodiazepine antagonist |
| Original sponsor |
Roche affiliate |
| FDA application |
NDA 019430 |
| Regulatory pathway |
New drug application |
| Current exclusivity |
None of commercial significance |
| Generic competition |
Yes |
| Biosimilar exposure |
Not applicable |
| Orange Book relevance |
Historic reference product and listed product information |
| Primary market |
Institutional and hospital use |
The Orange Book is relevant to Romazicon because it identifies approved reference products and any patent or exclusivity information associated with listed applications. Romazicon's commercial position is no longer protected by meaningful market exclusivity. The relevant competitive issue is abbreviated new drug application, or ANDA, competition rather than a pending exclusivity event. [2]
When did Romazicon lose exclusivity?
Romazicon lost practical exclusivity many years ago. Its current market position reflects the normal post-exclusivity life cycle of an injectable drug:
- Original brand launch and clinical adoption
- Expiration of applicable regulatory and patent protections
- Entry of generic flumazenil injections
- Conversion of hospital purchasing to contract and formulary channels
- Declining brand relevance and supplier-driven competition
The product has no remaining new chemical entity exclusivity. Any original patent protection would have expired decades ago under the U.S. patent term applicable to the relevant filing period.
What patents protect Romazicon?
No current patent estate appears to provide a material barrier to generic flumazenil injection in the United States. Romazicon is not a current high-value patent product.
The relevant protection categories are:
| Protection category |
Romazicon position |
| Active-ingredient patent |
Expired or commercially irrelevant |
| Formulation patent |
No known current barrier to standard flumazenil injection |
| Method-of-use patent |
No meaningful current exclusivity identified |
| Manufacturing patent |
Not a practical barrier to ordinary generic supply |
| Regulatory exclusivity |
Expired |
| Trademark |
Brand name protection does not prevent generic flumazenil sales |
The remaining intellectual-property value is primarily the Romazicon trademark and historical clinical recognition. Trademark rights do not prevent generic manufacturers from selling products under the nonproprietary name flumazenil.
What formulations are protected by Romazicon patents?
Romazicon was commercialized as an injectable flumazenil solution, generally supplied at a concentration of 0.1 mg/mL. The product does not have the type of complex delivery-system or device-related formulation protection seen with long-acting injectables, inhaled products, transdermal systems, or autoinjectors.
Generic competition is therefore technically feasible through a conventional sterile injectable formulation. Remaining barriers relate more to sterile manufacturing validation, preservative and container compatibility, quality systems, and reliable commercial-scale supply than to enforceable product patents.
How strong is the Romazicon patent estate?
The Romazicon patent estate is weak from a current commercial perspective.
| Patent-strength factor |
Assessment |
| Remaining term |
None of material commercial value |
| Patent thicket |
Absent |
| Complex formulation protection |
Limited |
| Manufacturing exclusivity |
Not evident |
| Method-of-use protection |
Not commercially meaningful |
| Generic design-around difficulty |
Low to moderate |
| Litigation leverage |
Low |
| Licensing leverage |
Low |
Generic manufacturers do not need to overcome a substantial patent thicket to commercialize standard flumazenil injection. The principal entry requirements are FDA approval, sterile injectable manufacturing capability, product quality, and access to hospital purchasing channels.
Which companies compete with Romazicon?
The competitive market consists primarily of generic flumazenil suppliers. The specific supplier roster can change because hospital injectables are subject to discontinuations, shortages, manufacturing transfers, and contract changes.
The competitive set includes:
- Generic injectable manufacturers with approved flumazenil ANDAs
- Hospital-pharmacy distributors
- Wholesalers and group purchasing organizations
- Compounded or repackaged products where permitted under applicable law
- Alternative clinical management strategies, including observation and supportive care
Flumazenil has no direct therapeutic substitute that produces the same pharmacologic reversal of benzodiazepine effects. Naloxone reverses opioid effects and is not a substitute for flumazenil. In many overdose cases, clinicians may choose monitoring and supportive care rather than administering a reversal agent.
This creates an unusual market structure: flumazenil has clinical differentiation at the mechanism level but limited commercial differentiation at the product level.
What are the main market dynamics for flumazenil injection?
Hospital demand is stable but narrow
Demand is linked to:
- Procedural sedation
- Endoscopy and ambulatory surgery
- Anesthesia reversal protocols
- Emergency-department overdose evaluation
- Intensive-care and inpatient use
- Hospital stocking requirements for emergency medications
Volume is not tied to a large chronic-disease population. Utilization is episodic and protocol-dependent.
Generic pricing controls the market
After generic entry, hospitals typically purchase flumazenil through formularies, wholesalers, group purchasing organizations, and multiyear supply contracts. Price competition can be significant, but sterile injectable markets can also experience sudden price increases when a supplier exits or a manufacturing site encounters disruption.
The market can therefore move between two conditions:
- Low-margin, highly competitive supply during normal availability
- Temporary price expansion during shortage or supplier concentration
Availability can matter more than nominal price
Hospitals may retain multiple suppliers or safety stock because flumazenil is an emergency-use product. A manufacturer with reliable supply, acceptable lead times, and a strong injectable portfolio can win share even without the lowest unit price.
For a mature injectable, commercial performance is often determined by:
- FDA compliance history
- Manufacturing continuity
- Fill-finish capacity
- Product presentation and vial size
- Wholesaler inventory
- Contract access
- Shortage performance
The FDA maintains a drug-shortage database for products that experience supply disruption or constrained availability. Flumazenil's commercial risk should be assessed through that supply channel rather than through brand-demand indicators alone. [3]
What is the financial trajectory for Romazicon?
Romazicon's financial trajectory is consistent with a mature, post-exclusivity hospital injectable:
| Period |
Financial condition |
| Launch and early adoption |
Brand-supported growth from clinical use and anesthesia adoption |
| Generic-entry period |
Revenue and price pressure from ANDA competition |
| Mature generic market |
Low brand visibility and fragmented supplier economics |
| Current state |
Limited standalone brand value; demand persists at the active-ingredient level |
Roche's public financial reports do not provide a separate Romazicon revenue line. The product is not identified as a material growth driver in the company's current portfolio disclosures. [4]
Generic manufacturers also generally do not disclose flumazenil revenue separately. Their filings group the product with broader portfolios of injectable and hospital medicines. As a result, a precise product-level revenue forecast cannot be supported by public company reporting.
The economic opportunity is likely modest in absolute terms but potentially attractive as part of a broader injectable portfolio. A supplier can obtain value through:
- Incremental manufacturing utilization
- Hospital contract placement
- Portfolio bundling
- Supply reliability premiums
- Temporary pricing during competitor outages
- Low promotional expenditure after formulary adoption
The principal downside is limited market size. Flumazenil is not a high-volume therapeutic franchise, and price competition can compress margins when several suppliers remain active.
What generic entry risks exist for Romazicon?
Generic entry risk is already realized rather than prospective. The relevant question is whether additional generic entrants or supplier exits will change pricing and availability.
Generic launch scenarios
| Scenario |
Market effect |
| New generic entrant |
Lower prices and greater supply redundancy |
| Existing supplier exit |
Higher shortage risk and possible price increases |
| Manufacturing warning or recall |
Temporary allocation and hospital purchasing disruption |
| Stable multi-source supply |
Low prices and limited brand relevance |
| Contract consolidation |
Share shifts toward the supplier with the strongest purchasing access |
A new entrant would face low patent risk but meaningful operational barriers. FDA approval of sterile injectables requires validated aseptic processing, container-closure integrity, stability data, quality controls, and compliant manufacturing. These requirements can discourage small manufacturers even when the product has no patent barrier.
Is there Paragraph IV litigation involving Romazicon?
Romazicon does not appear to present a current Paragraph IV litigation story of material commercial importance. Any historical ANDA challenges would relate to expired protection and would not create a present barrier to generic flumazenil sales.
Paragraph IV risk is therefore not the central investment issue. The more relevant questions are:
- How many approved suppliers remain active?
- Are products currently available through major wholesalers?
- Are manufacturers exposed to FDA warning letters or recalls?
- Does a supplier have adequate sterile capacity?
- Are hospital contracts concentrated among a small number of vendors?
No current settlement agreement is known to have strategic significance for the Romazicon market. The product's commercial profile is shaped by generic competition and supply execution rather than by branded litigation.
What is the biosimilar risk for Romazicon?
There is no biosimilar risk because flumazenil is a chemically synthesized small molecule, not a biologic. The applicable competitive pathway is the ANDA pathway for generic drugs, not the Biologics Price Competition and Innovation Act pathway for biosimilars.
This distinction matters commercially. Generic entry does not require clinical comparability studies of the type associated with biosimilars. The principal technical burden is pharmaceutical equivalence, bioequivalence where applicable, sterile manufacturing, and quality compliance.
What manufacturing and geographic barriers affect flumazenil?
The active ingredient is not the main barrier. The critical manufacturing constraints are associated with sterile injectable production.
Manufacturing barriers
- Aseptic filling and finishing
- Sterility assurance
- Container-closure integrity
- Batch release testing
- Stability and expiry dating
- Inspection readiness
- Reliable sourcing of vials, stoppers, and packaging
- Capacity allocation for low-volume products
Geographic coverage
The United States remains the principal reference market for Romazicon and generic flumazenil injection in this analysis. Flumazenil is also marketed internationally under different brand and generic names, but approval status, supplier participation, pricing, and reimbursement differ by country.
In Europe and other regulated markets, the product may be sold under national or regional brand names. Geographic expansion is unlikely to create large growth unless a manufacturer uses flumazenil as part of a broader hospital-injectable portfolio.
How does Romazicon compare with competing emergency medicines?
| Product |
Active ingredient |
Primary role |
Relationship to Romazicon |
| Romazicon |
Flumazenil |
Benzodiazepine reversal |
Reference product |
| Generic flumazenil |
Flumazenil |
Benzodiazepine reversal |
Direct substitute |
| Narcan and generic naloxone |
Naloxone |
Opioid reversal |
Different mechanism and indication |
| Supportive care |
None |
Airway, ventilation, observation |
Practical alternative in selected cases |
| Anesthetic reversal agents |
Various |
Reversal of other anesthetics |
Not direct substitutes |
The closest competitors are generic flumazenil products. Naloxone and supportive care compete for clinical decision-making in overdose settings but do not replace flumazenil pharmacologically.
What is the investment and licensing outlook for Romazicon?
Romazicon has limited standalone licensing value. A transaction centered only on the legacy brand would be unlikely to command a premium unless it included:
- A strong hospital distribution platform
- A broader injectable portfolio
- Manufacturing capacity
- Rights to multiple geographic markets
- A supply contract with major institutions
- A differentiated presentation or delivery format
The asset may have portfolio value for a generic manufacturer, contract manufacturer, or specialty hospital supplier. It is unlikely to support a high-growth branded-drug investment thesis.
Key Takeaways
- Romazicon is the original brand of flumazenil, an intravenous benzodiazepine antagonist.
- U.S. exclusivity expired long ago, and generic flumazenil injection is commercially available.
- No current patent estate appears to provide a material barrier to generic entry.
- The product has no biosimilar exposure because flumazenil is a small molecule.
- Standalone Romazicon revenue is not publicly disclosed by Roche.
- The market is small, hospital-centered, and driven by sterile supply reliability.
- Pricing is generally competitive, but supplier exits and manufacturing disruptions can create temporary price increases.
- The principal commercial risks are low volume, generic price pressure, and limited supplier depth.
- The principal opportunity is portfolio economics for a reliable generic injectable manufacturer, not branded-product growth.
- Current litigation, Paragraph IV activity, and settlement agreements do not appear to be major drivers of the market.
FAQs
Is Romazicon still sold in the United States?
Flumazenil remains available in the United States through generic injectable products. Availability of the original Romazicon-branded product may differ from availability of the active ingredient.
Is flumazenil a controlled substance?
Flumazenil is not a benzodiazepine and does not produce the same pharmacologic effects as benzodiazepine agonists. Its regulatory treatment differs from controlled benzodiazepine medicines.
Can naloxone replace Romazicon?
No. Naloxone reverses opioid effects, while flumazenil reverses benzodiazepine effects. They address different drug classes.
Why do hospitals stock flumazenil if it is used infrequently?
Hospitals may stock flumazenil for selected procedural-sedation complications, anesthesia reversal, and emergency cases despite low utilization because rapid access can be clinically important.
Is Romazicon a potential high-growth pharmaceutical asset?
No. Its commercial profile is mature and genericized. Any value is more likely to arise from reliable supply, hospital contracts, and portfolio integration than from branded growth or patent protection.
References
-
U.S. Food and Drug Administration. (2010). Romazicon (flumazenil) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drug shortages. FDA.
-
Roche Holding AG. (2023). Annual report 2023. Roche.
